CLL1 CAR-NK cell (Zhejiang University/Hangzhou Qihangene Biotech)

N/A

Report date: 2023/10/12 20:00:48

Base Information

Drug NameCLL1 CAR-NK cell (Zhejiang University/Hangzhou Qihangene Biotech)
Drug Alias NameCLL1 target CAR iPSC NK cells (Zhejiang University/Hangzhou Qihangene Biotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionC-Type lectin domain family 12 member A modulators
TargetsC-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang UniversityHangzhou Qihan Jiyin Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Qihan Jiyin Biotechnology Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A